Fuad Anshori, Teguh Triyono, Tri Ratnaningsih


The thrombocyte concentrate (TC) preparation process through its storage affects the platelets contained inside. The contaminating leukocytes in TC is an important factor implicated in storage lesion on TC during storage. Leukodepletion is a method to reduce contaminant leukocytes. Myeloperoxidase (MPO) is an enzyme produced by polymorphonuclear cells that have the potential to change structure and function of platelets when there is interaction between them during storage. The aim of this study is assessing the difference in myeloperoxidase level of TC based on its preparation method (leukodepleted and non-leukodepleted) and time storage. A cross-sectional observational study was conducted at the Blood Transfusion Services Unit, Dr. Sardjito hospital, Yogyakarta from April to December 2014. Thrombocyte Concentrate products was grouped based on storage time (≤ and >72 hours) and preparation method (leukodepleted and non-leukodepleted), their MPO was then measured. Mean difference in each group was analyzed using ANOVA test and post hoc test with statistical significance level of p < 0.05. There were 64 eligible subjects, consisted of 29 leukodepleted TCs and 35 non-leukodepleted TCs, based on their storage time, 31 TCs had ≤72 hours storage  time and the other 33 TCs > 72 hours. There were significantly lower median MPO level in ≤72 hours TCs than > 72 hours in non-leukodepleted TC group (13.23 ± 6.47 ng/mL vs 15.58 ± 7.82 ng/mL; p = 0.017). In TC group with more than 72 hours storage time, median MPO level in non-leukodepleted was significantly higher than leukodepleted TC (15.58 ± 7.82 ng/mL vs. 11.11 ± 3.97 ng/mL; p = 0,001). Myeloperoxidase level was lower in non-leukodepleted TC group with ≤ 72 hours than > 72 hours storage time. Furthermore, the MPO level was higher in leukodepleted TC than non-leukodepleted TC in > 72 hours storage time.


thrombocyte concentrate, storage time, leukodepleted, myeloperoxidase, storage lesion.


World Health Organization. Global database on blood safety. 2013. Available at: Downloaded Juny 2nd 2016.

Sahler J, Grimshaw K, Spinelli SL, et al. Platelet Sorage and Tranfusions : New Concerns associated With An Old Therapy. J DD Med. 2011; 8 : 1-2.

UPTD RSUP Dr. Sardjito. Laporan Pengeluaran Darah dan Rekapitulasi Pengeluaran Darah. Yogyakarta, 2011&2012.

Horvath M, Eichelberger B, Koren D, Bohm A, Ay C, Jilma-Stohlawetz B. Function of Platelets in Apheresis Platelet Concentrates and in Patient Blood after Transfusion as Assessed by Impact-R. J Trans. 2009; 50 : 59.

Gorudko IV, Cherkalina O S, Sokolov AV, et al. New approaches to the measurement of the concentration and peroxidase activity of myeloperoxidase in human blood plasma. Bioorg Khim. 2009; 35: 629-639.

Edvardsen L, Taaning E, Mynster T, et al. Bioactive substances in buffy-coat-derived platelet pools stored in platelet-additive solutions. Bristish Journal of Hematology. 1998; 103: 445-448.

Hyllner M. Prestorage Leukocyte Filtration on Blood : Effect on Cytokine Generation and Complement Activation. Current Aneaesthesia & Critical care. 2012; 15: 95-100.

Schiffer CA. Diagnosis and management of refractoriness to platelet transfusion. Blood Rev. 2001; 15(4): 175–180.

Stroncek DF dan Rebulla P. Transfusion Medicine 2, Platelet transfusion. The Lancet. 2007; 370: 427-438.

Blair P dan Flaumenhaft R. Platelet Alpha–granules: Basic biology and clinical correlates. Blood Rev. 2009; 23(4): 177-189.

Ghezelbash B, Kafiabad SA, Hojjati MT, et al. In Vitro Assessment of Platelet Lesions during 5-day Storage in Iranian Blood Transfusion Organization (IBTO) Centers. Archives of Iranian Medicine. 2015; 18: 2-5.

Chalandon Y, Mermillod B, Beris P. Benefit of prestorage leukocyte depletion of single-donor platelet concentrates. Vox Sang. 1999; 76(1): 27–37.

Elzey, BD, Sprague DL, Ratliff TL. The emerging role of platelets in adaptive immunity. Cell Immunol. 2005; 238: 1–9.

Silliman CC dan McLaughlin NJ. Transfusion-related acute lung injury. Blood Rev. 2006; 20: 139–159.

Murphy MF dan Waters AH. Platelet transfusions: the problem of refractoriness. Blood Rev. 1990; 4(1): 16–24.



  • There are currently no refbacks.